SK Biopharmaceuticals’ new epilepsy drug increases expectation for US FDA approval
A SK Biopharmaceuticals’ new epilepsy drug has been increasingly expected to acquire immediate approval from the U.S. FDA.
According to the industry concerned on the 15th, ‘YKP3089,’ a new epilepsy drug that is being developed by SK Biopharmaceuticals, a subsidiary of SK Group, has a high chanc...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
